

| Theme | Session Title | Presentation No. | Abstract No. | Lecture title | Speaker | Country |
|-------------------------------------|-----------------------------------|------------------|--------------|--|-----------------------|--------------|
| Tumor-type specific Sessions | Medulloblastoma (clinical) | MEDC-IS-01 | SPKR-57 | Medulloblastoma – Biology informs Clinical Outcome | Amar Gajjar | USA |
| | | MEDC-IS-02 | SPKR-42 | Bridging the treatment gap in infant medulloblastoma: Subgroup and subtype specific outcomes of a globally feasible regimen | Lorena Baroni | Argentina |
| | | MEDC-O-03 | MBCL-16 | Efficacy of carboplatin given concomitantly with radiation and isotretinoin as a pro-apoptotic agent in maintenance therapy in high-risk medulloblastoma: A report from the Children's Oncology Group | Sarah Leary | USA |
| | | MEDC-O-04 | MBCL-15 | Impact of molecular subgroups on outcomes following radiation treatment randomizations for average risk medulloblastoma: a planned analysis of Children's Oncology Group (COG) ACNS0331 | Jeff Michalski | USA |
| | | MEDC-O-05 | MBCL-08 | Integrative molecular analysis of patient-matched diagnostic and relapsed medulloblastomas | Rahul Kumar | USA |
| | | MEDC-O-06 | MBCL-34 | Efficacy of methotrexate (MTX) according to molecular sub-type in young children with medulloblastoma (MB): A report from Children's Oncology Group Phase III trial ACNS0334 | Claire Mazewski | USA |
| | | MEDC-P-07 | MBCL-21 | Germline elongator mutations in sonic hedgehog medulloblastoma | Giles Robinson | USA |
| | | MEDC-P-08 | MBCL-06 | Risk stratification improvement of the HIT2000 and I-HIT-MED cohorts using molecular subtypes I-VIII of Group 3/4 medulloblastomas | Martin Mynarek | Germany |
| | | MEDC-P-09 | MBCL-07 | Non-metastatic medulloblastoma of early childhood: Results from the prospective clinical trial HIT-2000 and an extended validation cohort | Martin Mynarek | Germany |
| | | MEDC-P-10 | MBCL-29 | Phase I/II study of sequential high-dose chemotherapy with stem cell support in children younger than 5 years of age with high-risk medulloblastoma. | Christelle Dufour | France |
| | | MEDC-P-11 | MBCL-36 | How to increase survival in 7 to 10% of patients with average-risk medulloblastoma without new therapies: early prospective neuroradiology screening experience from the Children's Oncology Group | Nicholas Gottardo | Australia |
| | | MEDC-P-12 | MBCL-02 | Role of preoperative chemotherapy in metastatic medulloblastoma: a comparative study in 92 children | Léa Guerrini-Rousseau | France |
| | | MEDC-P-13 | MBCL-25 | Pilot study of a surgery and chemotherapy-only approach in the upfront therapy of children with Wnt-positive standard risk medulloblastoma: Updated outcomes | Kenneth Cohen | USA |
| | | MEDC-P-14 | MBCL-09 | Isolated M1 metastases in pediatric medulloblastoma: is postoperative radiotherapy followed by maintenance chemotherapy superior to postoperative sandwich-chemotherapy and radiotherapy? | Denise Obrecht | Germany |
| | | MEDC-P-15 | MBCL-11 | Time to radiotherapy impacts survival in pediatric and adolescent non-metastatic medulloblastoma treated by upfront radiotherapy – A report from the HIT 2000 trial | Martin Mynarek | Germany |
| | | MEDC-P-16 | MBCL-03 | Results of high-dose thiotepa, carboplatin and etoposide with autologous hematopoietic stem-cell transplantation for patients with recurrent medulloblastoma | Asmik Gevorgian | Russia |
| | | MEDC-P-17 | MBCL-24 | Can young children with relapsed medulloblastoma be salvaged after initial irradiation-sparing approaches? | Craig Erker | Canada |
| | | MEDC-P-18 | MBCL-28 | Long-term follow-up results of reduced dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma | Ji Won Lee | Korea |
| | | MEDC-P-19 | MBCL-31 | Treatment results among 106 patients with medulloblastoma of molecular subgroup 3 | Olga Zheludkova | Russia |
| | | MEDC-P-20 | MBCL-51 | Post-autologous hematopoietic cell transplantation (AuHCT) practices for young children with malignant brain tumors | Scott Coven | USA |
| | | MEDC-P-21 | MBCL-26 | Factors associated with longer survival after first recurrence in medulloblastoma by molecular subgroup after risk-based initial therapy | Murali Chintagumpala | USA |
| | | MEDC-P-22 | MBCL-52 | Endocrine profile after medulloblastoma treatment | Martin English | UK |
| | | MEDC-P-23 | MBCL-12 | Molecular signatures and tumor infiltrating immunological cells associated with Asian medulloblastoma patient survival | Kung-Hao Liang | Taiwan |
| | | MEDC-P-24 | MBCL-19 | Chemotherapy strategies for young children newly diagnosed with desmoplastic/extensive nodular medulloblastoma up to the era of molecular profiling – a comparative outcomes analysis of prospective multi-center European and North American trials | Jonathan Finlay | USA |
| | | MEDC-P-25 | MBCL-20 | Detection of somatic mutations by using RNA-Seq data in childhood medulloblastoma and its potential clinical application: A cohort series of 52 cases study in Taiwan | Tai-Tong Wong | Taiwan |
| | | MEDC-P-26 | MBCL-43 | Recurrent medulloblastoma – long-term survival with a "MEMMAT" based antiangiogenic approach | Irene Slavc | Austria |
| | | MEDC-P-27 | MBCL-48 | Outcomes of treatment based on the St. Jude medulloblastoma-96 regimen for Japanese children with medulloblastoma | Junya Fujimura | Japan |
| | | MEDC-P-28 | MBCL-01 | Methylation profiling of pediatric medulloblastoma in Saudi Arabia in a clinical setting permits sub-classification and reveals new outcome predictions | Nahla Mobark | Saudi Arabia |
| | | MEDC-P-29 | MBCL-05 | Treatment of children with medulloblastoma without metastatic involvement in the age group older than 3 years: results of intercenter trial | Andrey Levashov | Russia |
| | | MEDC-P-30 | MBCL-17 | Metastatic medulloblastoma can be cured without excision of the primary tumor: A single center experience. | Rina Dvir | Israel |
| | | MEDC-P-31 | MBCL-22 | Efficacy of double-conditioning regimen comprising thiotepa and melphalan for relapsed medulloblastoma – a single institution experience | Kai Yamasaki | Japan |
| | | MEDC-P-32 | MBCL-23 | Preliminary analysis of treatment-related toxicities during induction chemotherapy for patients on the Head Start 4 trial | Vibhuti Agarwal | USA |
| | | MEDC-P-33 | MBCL-38 | Unusual extraneural metastasis of pediatric embryonal tumors: two case reports | Ashley Plant | USA |
| | | MEDC-P-34 | MBCL-04 | 5 – azacytidine in treatment of children with de novo and relapsed metastatic medulloblastoma: results of intercenter pilot study | Andrey Levashov | Russia |
| | | MEDC-P-35 | MBCL-35 | Salvage radiation therapy for progressive and/or relapsed pediatric medulloblastoma | Muhammad Baig | USA |
| | | MEDC-P-36 | MBCL-10 | Local recurrence and survival outcomes of medulloblastoma (MB) in adolescent and young adult patients (AYA) | Warissara Rongthong | Thailand |
| | | MEDC-P-37 | MBCL-13 | Correlation of histopathology, chromosomal microarray, and NanoString based 22-gene assay for medulloblastoma subgroup assignment on "Head Start" 4 clinical trial | Girish Dhall | USA |
| | | MEDC-P-38 | MBCL-18 | Analysis of DNA methylation profiles of pediatric medulloblastomas: experience at the Bambino Gesù Children's Hospital | Evelina Miele | Italy |
| | | MEDC-P-39 | MBCL-32 | High-dose chemotherapy with stem cell rescue for recurrent previously irradiated medulloblastoma | Ekaterina Salnikova | Russia |
| | | MEDC-P-40 | MBCL-46 | Treatment of recurrent wingless-activated medulloblastoma (Wnt-MB) incorporating marrow-ablative thiotepa and carboplatin chemotherapy (HDCx) and autologous hematopoietic progenitor cell rescue (AuHPCR): a dual report | Micah Harris | USA |
| | | MEDC-P-41 | MBCL-50 | Dismal outcome of high risk medulloblastoma treated with chemotherapy first approach in Malaysia | Shiao Wei Quah | Malaysia |
| | | MEDC-P-42 | MBCL-33 | Rare pulmonary toxicity in three medulloblastoma patients undergoing antiangiogenic metronomic combination therapy | Alicia Lenzen | USA |
| | | MEDC-P-43 | MBCL-14 | A study of low-dose craniospinal radiation therapy in patients with newly diagnosed average-risk medulloblastoma | Aaron Mochizuki | USA |
| | | MEDC-P-44 | MBCL-41 | Lymphohematopoietic toxicity identified in patients with medulloblastoma receiving craniospinal irradiation | Atsuko Watanabe | Japan |
| | | MEDC-P-45 | MBCL-27 | Association of medulloblastoma with Charcot-Marie-Tooth disease | Kenichiro Watanabe | Japan |
| | | MEDC-P-46 | MBCL-30 | Novel SMO mutation in desmoplastic/nodular medulloblastoma: a case report | Avery Wright | USA |
| | | MEDC-P-47 | MBCL-37 | Chemotherapy strategies for young children newly diagnosed with classic (CIMB) or anaplastic/large cell (ALCMB) medulloblastoma up to the era of molecular profiling – a comparative outcomes analysis | Jonathan Finlay | USA |